OptimizeRx Corporation OPRX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -23.98%
- 1 year
- -52.47%
- Open
- 9.25
- Prev close
- 9.37
- Mkt cap
- 175.55M
- Vol
- 136.55K
- Avg vol
- 182.57K
- EPS
- 0.24
- P/E
- 38.83
- Div yield
- 0.00%
More statistics
- Low
- 9.03
- High
- 9.36
- Forward P/E
- 9.86
- Beta
- 0.00
- Short ratio
- 2.70
- Inst. own
- 68.94%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.40
- 200-d avg
- 8.91
- 1y target
- 10.36
News
4 days ago globenewswire.com
OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET
WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
5 days ago globenewswire.com
OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel
Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows Latest DSP integration expands buyer access to OptimizeRx point of care…
-
1 month ago benzinga.com
B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.
1 month ago zacks.com
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
1 month ago globenewswire.com
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare…
1 month ago seekingalpha.com
OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook
OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic…
1 month ago defenseworld.net
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies…
1 month ago globenewswire.com
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow New functionality helps DSPs and agency planners create…
1 month ago globenewswire.com
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
2 months ago globenewswire.com
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
2 months ago defenseworld.net
AWM Investment Company Inc. Invests $1.38 Million in OptimizeRx Corp. $OPRX
AWM Investment Company Inc. acquired a new stake in OptimizeRx Corp. (NASDAQ: OPRX) in the undefined quarter, according to the company in its most recent filing with the SEC. The firm acquired…
-
2 months ago benzinga.com
Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11
Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.
2 months ago defenseworld.net
Dimensional Fund Advisors LP Purchases 102,661 Shares of OptimizeRx Corp. $OPRX
Dimensional Fund Advisors LP grew its position in shares of OptimizeRx Corp. (NASDAQ: OPRX) by 22.3% during the undefined quarter, according to the company in its most recent filing with the…
2 months ago marketbeat.com
OptimizeRx Q2 Earnings Call Highlights
OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its…
2 months ago seekingalpha.com
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.
-
2 months ago benzinga.com
OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est
OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.
-
2 months ago benzinga.com
OptimizeRx Q2 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $20.504M Beat $20.204M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 33.33 percent decrease over earnings of $0.24…
2 months ago globenewswire.com
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027
2 months ago globenewswire.com
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
– Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted…
3 months ago globenewswire.com
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
3 months ago globenewswire.com
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
-
4 months ago benzinga.com
OptimizeRx Rolls Out CopayCue To Provide Enhanced Brand Savings For Physicians
OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at…
4 months ago globenewswire.com
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the…
4 months ago globenewswire.com
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology…
-
5 months ago benzinga.com
OptimizeRx's Electronic Health Record Network Integrated By DeepIntent
OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important…
-
5 months ago benzinga.com
Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11
Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $20 to $11.
-
5 months ago benzinga.com
B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
5 months ago benzinga.com
Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.
-
5 months ago benzinga.com
Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.
-
5 months ago benzinga.com
OptimizeRx Reports Q1 2026 Results: Full Earnings Call Transcript
OptimizeRx Reports Q1 2026 Results: Full Earnings Call Transcript
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
5 months ago benzinga.com
OptimizeRx Lowers FY2026 Sales Guidance from $109.000M-$114.000M to $95.000M-$100.000M vs $111.438M Est
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.000 million-$100.000 million vs $111.438 million estimate.
-
5 months ago benzinga.com
OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 75 percent increase over earnings of $0.08…
-
5 months ago benzinga.com
OptimizeRx Launches New Programmatic Connection Point Between OptimizeRx's Proprietary EHR Network And DSPs
OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
8 months ago benzinga.com
Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $20
Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $24 to $20.
8 months ago benzinga.com
OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty
OptimizeRx CEO warns of increased market volatility and uncertainty around MFN pricing. Lower 2026 forecasts due to cautious spending.
8 months ago benzinga.com
Assessing OptimizeRx: Insights From 4 Financial Analysts
Assessing OptimizeRx: Insights From 4 Financial Analysts
-
8 months ago benzinga.com
Roth Capital Maintains Buy on OptimizeRx, Lowers Price Target to $18
Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $32 to $18.
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
8 months ago benzinga.com
B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $11
B. Riley Securities analyst Anderson Schock reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $28 to $11.
-
8 months ago benzinga.com
Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $10
Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $17 to $10.
-
8 months ago benzinga.com
Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $17
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $21 to $17.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
8 months ago benzinga.com
OptimizeRx Lowers FY2026 Sales Guidance from $118.000M-$124.000M to $109.000M-$114.000M
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.000 million-$114.000 million.
-
8 months ago benzinga.com
OptimizeRx Q4 Adj. EPS $0.51 Beats $0.23 Estimate, Sales $32.200M Beat $31.100M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.23 by 124.67 percent. This is a 70 percent increase over earnings of $0.30 per…
-